Finland's Biotie Therapies Renegotiates Nalmefene Deal And Receives €30 Million Funding Lifeline
This article was originally published in The Pink Sheet Daily
With the end of its cash runway on the horizon, Finland’s Biotie Therapies has received an equity investment of €10 million from Lundbeck and €20 million from institutional investors, after renegotiating the ex-Europe part of its worldwide nalmefene licensing pact.
You may also be interested in...
NICE's positive recommendation for Lundbeck's Selincro for alcohol dependence should give the Danish biotech a revenue boost and help offset expiry of its Lexapro/Cipralex patent.
Biotie Therapies gets $20 million as UCB exercises its option on the investigational Parkinson's disease therapy tozadenant and asks the Finnish biotech to continue its clinical development of the product into Phase III.
Europe's top scientific advisory panel backed Lundbeck's alcoholism therapy Selincro (nalmefene) and Roche's next-generation breast cancer therapy Perjeta (pertuzumab) but rejected Genzyme/Isis' antisense therapy Kynamro (mipomersen) and Vanda's Fanaptum (oral iloperidone).